Clifford Swan Investment Counsel LLC Lowers Stock Holdings in Pfizer Inc. $PFE

Key Points

• Clifford Swan Investment Counsel LLC has reduced its holdings in Pfizer Inc. by 4.6%, selling 27,572 shares during the second quarter, which leaves them with 569,172 shares valued at approximately $13.8 million.
• Pfizer recently beat earnings estimates for the last quarter, reporting $0.78 EPS against a consensus estimate of $0.58 and a revenue of $14.65 billion, exceeding expectations of $13.43 billion.
• The company declared a quarterly dividend of $0.43 per share, which will be paid on December 1st, representing an annual yield of 7.0% and a high dividend payout ratio of 91.49%.

Clifford Swan Investment Counsel LLC lessened its position in Pfizer Inc. (NYSE:PFE - Free Report) by 4.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 569,172 shares of the biopharmaceutical company's stock after selling 27,572 shares during the quarter. Clifford Swan Investment Counsel LLC's holdings in Pfizer were worth $13,797,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Bessemer Group Inc. increased its stake in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after purchasing an additional 13,228 shares during the period. Capital Advisors Inc. OK increased its stake in Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after buying an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp acquired a new stake in Pfizer during the 1st quarter worth approximately $8,283,000. Westbourne Investments Inc. acquired a new stake in Pfizer during the 1st quarter worth approximately $2,411,000. Finally, Bourne Lent Asset Management Inc. boosted its position in Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock valued at $927,000 after buying an additional 18,200 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Down 0.5%

PFE opened at $24.72 on Thursday. The business's 50-day simple moving average is $24.88 and its 200-day simple moving average is $24.13. The company has a market cap of $140.52 billion, a P/E ratio of 13.15, a PEG ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.17. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the company posted $0.60 earnings per share. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on PFE shares. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. UBS Group restated a "neutral" rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Citigroup increased their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley decreased their price objective on Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a research note on Friday, October 10th. Finally, Bank of America raised their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.